Antibiotic Susceptibility Testing Takes 2-3 Days, Forcing Empiric Prescribing That Drives Resistance

When a patient has a bacterial infection, doctors must prescribe antibiotics immediately without knowing which antibiotic will work. Traditional culture-based susceptibility testing takes 2-3 days. This forces broad-spectrum empiric prescribing that drives antibiotic resistance.

Standard AST requires overnight culture (16-24h) followed by susceptibility testing (another 16-24h). Rapid molecular methods (PCR-based) can identify resistance genes in 1-2 hours but only detect known resistance mechanisms, missing novel ones. Phenotypic rapid AST platforms (e.g., Accelerate Diagnostics' Pheno system, Specific Diagnostics' Reveal) aim to provide phenotypic results in 4-7 hours but have limited pathogen coverage. Single-cell morphological analysis and Raman spectroscopy approaches are in development for <2 hour AST.

Why It Matters

30-50% of empiric antibiotic prescriptions are suboptimal. Inappropriate antibiotic use is the primary driver of resistance. Faster AST could reduce broad-spectrum antibiotic use by 30-50%, slowing resistance emergence. Critical for ICU patients where infection mortality increases 7.6%/hour without appropriate antibiotics.

Startup Approach

Develop a universal rapid phenotypic AST platform that provides results in <2 hours directly from positive blood cultures. Use microfluidics + time-lapse imaging + AI to detect bacterial growth/inhibition at the single-cell level. FDA 510(k) pathway through comparison to standard AST.

NIH Funding

NIAID funds rapid diagnostic development for AMR. BARDA funds through CARB-X. NIBIB supports POC diagnostic technology.

Who's Working On It

Accelerate Diagnostics (Pheno system), Specific Diagnostics (Reveal), Day Zero Diagnostics (genomic AST), Qvella (FAST System), BioMérieux (VITEK rapid)